

PROVIDER QUICK POINTS

PROVIDER INFORMATION



June 14, 2023

Commercial Pharmacy Benefit Exclusion for Aponvie™, Iheezo™, Omisirge®, and Qalsody™

Effective **June 14, 2023**, the drugs listed in the table below will be excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
Aponvie™ (aprepitant) emulsion for intravenous (IV) infusion
Iheezo™ (chlorprocaine hcl) gel for topical ophthalmic use
Omisirge® (omidubicel-only) suspension for intravenous (IV) infusion
Qalsody™ (tofersen) solution for intrathecal administration

Products Impacted

These exclusions apply to commercial lines of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.